Table 2.

The mean serum uric acid, flow-mediated dilation (FMD), and mean systolic (SBP) and diastolic (DBP) blood pressure at baseline and 16 weeks later

Allopurinol Group (n = 30)Hyperuricemic Control Group (n = 37)Normouricemic Control Group (n = 30)
Baseline16 weeksPBaseline16 weeksPBaseline16 weeksP
Uric acid (mg/dl)8.3 ± 1.15.8 ± 1.5<0.0017.9 ± 0.77.2 ± 0.830.704.4 ± 0.94.5 ± 0.860.26
FMD (%)7.74 ± 0.938.12 ± 1.560.0037.76 ± 0.867.77 ± 0.850.529.16 ± 0.659.24 ± 0.660.18
eGFR (ml/min per 1.73 m2)86.3 ± 19.489.6 ± 12.60.00184.3 ± 16.784.4 ± 16.30.7792.8 ± 13.793.3 ± 9.20.63
hsCRP (mg/dl)7.4 ± 5.84.6 ± 3.70.0036.9 ± 3.45.9 ± 3.80.043.3 ± 2.53.4 ± 2.20.79
Mean SBP (mmHg)127.6 ± 14.4116.9 ± 11.70.005123.2 ± 13.5116.8 ± 9.90.26119.4 ± 11.2116.4 ± 13.40.46
Mean DBP (mmHg)75.1 ± 7.874.9 ± 12.40.1975.6 ± 8.773.9 ± 13.90.2277.3 ± 6.176.2 ± 11.80.39
  • The bold values indicate P < 0.05, statistically significant. eGFR, estimated GFR; hsCRP, highly-sensitive C-reactive protein.